Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools operating margin
Operating margin is operating income as a percentage of revenue.
Standard BioTools's operating margin for the twelve months ending Jun 30, 2026 was -112.8%. For fiscal 2025 it was -129.2%, against -140.1% the year before. The highest annual figure on record is -26.2% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -129.2% | +10.9 |
| FY2024 | Dec 31, 2024 | -140.1% | −68.0 |
| FY2023 | Dec 31, 2023 | -72.0% | +46.6 |
| FY2022 | Dec 31, 2022 | -118.6% | −67.0 |
| FY2021 | Dec 31, 2021 | -51.7% | −14.7 |
| FY2020 | Dec 31, 2020 | -36.9% | +7.3 |
| FY2019 | Dec 31, 2019 | -44.2% | −1.6 |
| FY2018 | Dec 31, 2018 | -42.6% | +14.6 |
| FY2017 | Dec 31, 2017 | -57.3% | +12.8 |
| FY2016 | Dec 31, 2016 | -70.1% | −26.4 |
| FY2015 | Dec 31, 2015 | -43.7% | +0.8 |
| FY2014 | Dec 31, 2014 | -44.5% | −18.3 |
| FY2013 | Dec 31, 2013 | -26.2% | +8.3 |
| FY2012 | Dec 31, 2012 | -34.5% | +8.8 |
| FY2011 | Dec 31, 2011 | -43.3% | +0.1 |
| FY2010 | Dec 31, 2010 | -43.4% | +27.6 |
| FY2009 | Dec 31, 2009 | -71.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -126.3% | −8.2 |
| Q1 FY2026 | Mar 31, 2026 | -59.1% | +74.3 |
| Q4 FY2025 | Dec 31, 2025 | -103.6% | +1.7 |
| Q3 FY2025 | Sep 30, 2025 | -168.5% | −47.6 |
| Q2 FY2025 | Jun 30, 2025 | -118.1% | +16.5 |
| Q1 FY2025 | Mar 31, 2025 | -133.4% | −1.2 |
| Q4 FY2024 | Dec 31, 2024 | -105.3% | −29.4 |
| Q3 FY2024 | Sep 30, 2024 | -120.9% | −37.4 |
| Q2 FY2024 | Jun 30, 2024 | -134.5% | −71.5 |
| Q1 FY2024 | Mar 31, 2024 | -132.2% | −66.1 |
| Q4 FY2023 | Dec 31, 2023 | -75.9% | +2.3 |
| Q3 FY2023 | Sep 30, 2023 | -83.5% | +29.7 |
| Q2 FY2023 | Jun 30, 2023 | -63.1% | +142.3 |
| Q1 FY2023 | Mar 31, 2023 | -66.1% | +37.7 |
| Q4 FY2022 | Dec 31, 2022 | -78.1% | −48.7 |
| Q3 FY2022 | Sep 30, 2022 | -113.2% | −44.4 |
| Q2 FY2022 | Jun 30, 2022 | -205.4% | −149.7 |
| Q1 FY2022 | Mar 31, 2022 | -103.8% | −44.9 |
| Q4 FY2021 | Dec 31, 2021 | -29.4% | +8.5 |
| Q3 FY2021 | Sep 30, 2021 | -68.8% | −55.1 |
| Q2 FY2021 | Jun 30, 2021 | -55.7% | −3.0 |
| Q1 FY2021 | Mar 31, 2021 | -58.9% | −4.8 |
| Q4 FY2020 | Dec 31, 2020 | -37.9% | −9.6 |
| Q3 FY2020 | Sep 30, 2020 | -13.7% | +38.4 |
| Q2 FY2020 | Jun 30, 2020 | -52.7% | −0.8 |
| Q1 FY2020 | Mar 31, 2020 | -54.1% | −6.9 |
| Q4 FY2019 | Dec 31, 2019 | -28.3% | +6.1 |
| Q3 FY2019 | Sep 30, 2019 | -52.1% | −12.0 |
| Q2 FY2019 | Jun 30, 2019 | -51.9% | −3.5 |
| Q1 FY2019 | Mar 31, 2019 | -47.2% | +2.9 |
| Q4 FY2018 | Dec 31, 2018 | -34.4% | −2.9 |
| Q3 FY2018 | Sep 30, 2018 | -40.1% | +22.9 |
| Q2 FY2018 | Jun 30, 2018 | -48.4% | +20.6 |
| Q1 FY2018 | Mar 31, 2018 | -50.0% | +18.6 |
| Q4 FY2017 | Dec 31, 2017 | -31.5% | +39.1 |
| Q3 FY2017 | Sep 30, 2017 | -63.0% | +20.2 |
| Q2 FY2017 | Jun 30, 2017 | -68.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -68.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -70.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -83.3% | – |
See a number that looks wrong?